Perspectives on assessing benefits and risks in clinical trials for Alzheimer's disease.
Balancing benefits and risks in the development of treatments for Alzheimer's disease is challenging given the nature of the disease but critically important to ensure effective treatments are available. Drawing on a diverse panel of scientists, regulators, caregivers, patients and advocates convened by the Alzheimer's Association, insights are offered into benefit/risk assessment, decision-making, regulatory and societal factors affecting clinical trials on AD. Several policy solutions are offered to improve the drug testing, review and approval process.
McConnell
Stephen
S
Alzheimer's Association, Washington, DC, USA. Stephen.McConnell@alz.org
Karlawish
Jason
J
Vellas
Bruno
B
DeKosky
Steven
S